What is the 13F Pro Quality Score for VRTX?

13F Pro ranks VERTEX PHARMACEUTICALS INC / MA (VRTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VRTX's current score at https://13fpro.ai/company/VRTX (free sign-up required for the full ranking).

Where does 13F Pro source VRTX data?

All VERTEX PHARMACEUTICALS INC / MA fundamentals and ownership data come directly from SEC EDGAR. VERTEX PHARMACEUTICALS INC / MA files with the SEC under CIK 875320. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VRTX in?

VERTEX PHARMACEUTICALS INC / MA (VRTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives VRTX's revenue?

Per VERTEX PHARMACEUTICALS INC / MA's latest 10-Q filed with the SEC on 2026-08-04, the biggest revenue drivers are: TRIKAFTA/KAFTRIO ($2,497.2M, -2% YoY); ALYFTREK ($573.6M, +266% YoY); Other CF product revenues (KALYDECO, ORKAMBI, SYMDEKO/SYMKEVI) ($137.1M, -29% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/VRTX.

What are VRTX's largest expenses?

VERTEX PHARMACEUTICALS INC / MA's latest 10-Q reports these as the largest expense items: Research and development expenses ($993.8M, +2% YoY); Selling, general and administrative expenses ($582.2M, +37% YoY); Cost of sales ($489.2M, +20% YoY). Sourced directly from SEC EDGAR filing text for Q2 2026 (quarter ended June 30, 2026).

How often is VRTX research updated on 13F Pro?

VRTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

VERTEX PHARMACEUTICALS INC / MA(VRTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 875320 VRTX stock profile & AI dashboard →

13F Pro Quality Score

75.4/100

Rank #98 of 2,961 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

61.0/100

Profitability

94.3/100

Balance Sheet

94.6/100

Earnings Quality

61.0/100

Free Cash Flow

84.2/100

Institutional Flow

76.5/100

Revenue Scale

88.5/100

Dilution Risk

22.9/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why VRTX Scores 75/100

exact factor attribution · 2026-09-11

VRTX's composite is driven by profitability and scale, held back by shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+6.6 pts

94th pct

Scale

+5.8 pts

89th pct

Free cash flow

+5.1 pts

84th pct

Capital efficiency

+4.5 pts

95th pct

Revenue growth

+2.2 pts

61th pct

Institutional flow

+1.3 pts

77th pct

Earnings quality

+1.1 pts

61th pct

Earnings growth

+0.2 pts

53th pct

Shareholder dilution

-1.4 pts

23th pct

Latest change (2026-08-08): 77 → 75 · ↓ Revenue growth 61→52; ↓ Institutional flow 46→36

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

VRTX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for VERTEX PHARMACEUTICALS INC / MA (VRTX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VRTX at 75.4/100 on a 32-signal composite quality model, placing it at rank #98 of 2,961 stocks — the top 5% of the AI-ranked universe. VRTX scores in the top quartile across balance sheet strength (94.6), profitability (94.3), revenue scale (88.5). Shareholder dilution risk is elevated at 22.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), VERTEX PHARMACEUTICALS INC / MA reports quarterly revenue of $3.3B, net income of $1.1B, an operating margin of 37.4%. Top institutional holders of VRTX by reported 13-F value include Capital World Investors, BlackRock, Capital Research Global Investors, based on the most recent SEC filings. VRTX trades on the Nasdaq exchange and files with the SEC under CIK 875320. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VRTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for VERTEX PHARMACEUTICALS INC / MA directly from SEC EDGAR. VERTEX PHARMACEUTICALS INC / MA's 13F Pro composite quality score has ranged between 45 and 87 since 2021, currently 75.4 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about VERTEX PHARMACEUTICALS INC / MA

Quirks, history, and lore behind VRTX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · large-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Annual revenue around $10 billion with operating margins that make most pharma companies jealous — north of 40% — built almost entirely on a single disease area.
3
The History
Founded in 1989, it spent decades as a research-stage company before cracking one of medicine's toughest nuts: a genetic disease once thought essentially untreatable.
4
The Secret
It doesn't treat symptoms — it targets the underlying protein defect caused by mutations in a single gene, a landmark shift in how rare genetic diseases are approached.
5
The Lore
Its blockbuster combo therapy Trikafta was called a near-miracle by patient groups and transformed the life expectancy outlook for people with a chronic lung disease affecting tens of thousands in the U.S.
6
The Giveaway
The dominant force in cystic fibrosis treatments, its modulators reach the vast majority of CF patients eligible for therapy — and it's now pushing into pain, kidney disease, and gene editing.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving VRTX's Business? Latest 10-Q Breakdown

✓ 29/29 datapoints verified

AI-extracted from VERTEX PHARMACEUTICALS INC / MA's 10-Q filed 2026-08-04 — Q2 2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Total revenues rose 12% to $3.3B as ALYFTREK scaled to $573.6M, offsetting a 2% TRIKAFTA/KAFTRIO decline, while Vertex agreed to acquire Crinetics for ~$10.0 billion.

Biggest Revenue Drivers

TRIKAFTA/KAFTRIO$2,497.2M-2% YoY

CF franchise revenue shifting as patients initiate ALYFTREK

ALYFTREK$573.6M+266% YoY

Reimbursement secured in four additional countries, bringing total reimbursed countries to 25

Biggest Revenue Drivers

Total revenue: $3.3B+12% YoY

TRIKAFTA/KAFTRIO$2,497.2M-2% YoY

CF franchise revenue shifting as patients initiate ALYFTREK

ALYFTREK$573.6M+266% YoY

Reimbursement secured in four additional countries, bringing total reimbursed countries to 25

Other CF product revenues (KALYDECO, ORKAMBI, SYMDEKO/SYMKEVI)$137.1M-29% YoY

CASGEVY$76.4M+151% YoY

FDA approval in children two years and older; German reimbursement secured for patients 12 and older

JOURNAVX$49.6M+313% YoY

Approximately 535,000 prescriptions filled in the quarter across hospital and retail settings

Largest Expense Items

Research and development expenses$993.8M+2% YoY

Investment in povetacicept, T1D, peripheral neuropathic pain and AMKD programs; offset by 2025 program discontinuations

Selling, general and administrative expenses$582.2M+37% YoY

Increased internal headcount and commercial investment to support JOURNAVX and the anticipated povetacicept launch in IgAN

Cost of sales$489.2M+20% YoY

Third-party CF royalties plus inventory costs; product mix shift raised the rate

Acquired in-process research and development expenses$21.4Mvs $2.2M a year ago

Upfront and milestone payments under collaboration and in-licensing arrangements

Margins: Cost of sales rose to 14.7% of net product revenues from 13.8%, driven by changes in product mix, partially offset by a lower blended royalty rate for CF medicines.

Watch Items from the Filing

Royalty Pharma arbitration alleges ALYFTREK royalty burden is approximately 8% versus Vertex's 4% position; ALYFTREK net revenues total $1.8B since inception.
Pending $10.0B Crinetics acquisition funded partly by a new $4.5B term loan; Vertex expects future net interest income (currently $120.6M quarterly) to decrease.
CF products remain $3,207.9M of $3,333.9M total revenues; TRIKAFTA/KAFTRIO fell 2% and other CF products fell 29% year over year.
SG&A up 37% to $582.2M ahead of the povetacicept IgAN launch, with a PDUFA target action date of November 30, 2026.
Ex-U.S. revenues of $1,277.5M grew 14%, aided by foreign exchange; $4.6B notional of currency forwards hedge forecasted revenues.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$3.3B

Net Income

Q2 2026

$1.1B

Free Cash Flow

Q2 2026

$1.0B

Operating Margin

Q2 2026

37.4%

ROIC

Q2 2026

24.6%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+8.9% YoY

$12.00BFY 2025

FY22 $8.93BFY23 $9.87BFY24 $11.02BFY25 $12.00B

Net Income

+838.1% YoY

$3.95BFY 2025

FY22 $3.32BFY23 $3.62BFY24 $-535.6MFY25 $3.95B

Operating Income

+1891.9% YoY

$4.17BFY 2025

FY22 $4.31BFY23 $3.83BFY24 $-232.9MFY25 $4.17B

EPS (Diluted)

+836.5% YoY

$15.32FY 2025

FY22 $12.82FY23 $13.89FY24 $-2.08FY25 $15.32

Total Assets

+13.8% YoY

$25.64BFY 2025

FY22 $18.15BFY23 $22.73BFY24 $22.53BFY25 $25.64B

Op. Cash Flow

+837.2% YoY

$3.63BFY 2025

FY22 $4.13BFY23 $3.54BFY24 $-492.6MFY25 $3.63B

Free Cash Flow

+504.1% YoY

$3.19BFY 2025

FY22 $3.93BFY23 $3.34BFY24 $-790.3MFY25 $3.19B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$12.00B +8.9%	$11.02B +11.7%	$9.87B +10.5%	$8.93B +17.9%	$7.57B +22.1%	$6.21B
Net Income	$3.95B +838.1%	$-535.6M -114.8%	$3.62B +9.0%	$3.32B +41.8%	$2.34B -13.6%	$2.71B
Operating Income	$4.17B +1891.9%	$-232.9M -106.1%	$3.83B -11.0%	$4.31B +54.8%	$2.78B -2.6%	$2.86B
EPS (Diluted)	$15.32 +836.5%	$-2.08 -115.0%	$13.89 +8.3%	$12.82 +42.3%	$9.01 -12.4%	$10.29
Total Assets	$25.64B +13.8%	$22.53B -0.9%	$22.73B +25.2%	$18.15B +35.1%	$13.43B +14.3%	$11.75B
Operating Cash Flow	$3.63B +837.2%	$-492.6M -113.9%	$3.54B -14.3%	$4.13B +56.2%	$2.64B -18.7%	$3.25B
Free Cash Flow	$3.19B +504.1%	$-790.3M -123.7%	$3.34B -15.0%	$3.93B +63.0%	$2.41B -19.5%	$2.99B

Get alerted when VRTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for VERTEX PHARMACEUTICALS INC / MA including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VRTX

Capital World Investors
$13.0B26,115,014 sh
BlackRock, Inc.
$12.0B24,109,373 sh
Capital Research Global Investors
$9.7B19,490,637 sh
VANGUARD CAPITAL MANAGEMENT LLC
$8.2B16,580,713 sh
STATE STREET CORP
$5.9B11,871,459 sh
Invesco Ltd.
$4.0B8,043,052 sh
JPMORGAN CHASE & CO
$3.3B6,517,600 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.0B6,017,848 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.4B4,878,987 sh
Capital International Investors
$2.3B4,695,144 sh

Fund	Value	Shares
Capital World Investors	$13.0B	26,115,014
BlackRock, Inc.	$12.0B	24,109,373
Capital Research Global Investors	$9.7B	19,490,637
VANGUARD CAPITAL MANAGEMENT LLC	$8.2B	16,580,713
STATE STREET CORP	$5.9B	11,871,459
Invesco Ltd.	$4.0B	8,043,052
JPMORGAN CHASE & CO	$3.3B	6,517,600
GEODE CAPITAL MANAGEMENT, LLC	$3.0B	6,017,848
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.4B	4,878,987
Capital International Investors	$2.3B	4,695,144

Companies Similar to VRTX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

REGN

REGENERON PHARMACEUTICALS, INC.

AI score

Very similar · 42 shared holders

LOOMIS SAYLES & CO L P Capital World Investors National Pension Service

BMY

BRISTOL MYERS SQUIBB CO

AI score

Very similar · 40 shared holders

Capital International Investors National Pension Service Robeco Institutional Asset Management B.V.

ABT

ABBOTT LABORATORIES

AI score

Very similar · 35 shared holders

Capital Research Global Investors Capital International Investors National Pension Service

ISRG

INTUITIVE SURGICAL INC

AI score

Very similar · 41 shared holders

Capital World Investors JENNISON ASSOCIATES LLC LOOMIS SAYLES & CO L P

SYK

STRYKER CORP

AI score

Very similar · 29 shared holders

Capital Research Global Investors Clearbridge Investments, LLC National Pension Service

Edwards Lifesciences Corp

AI score

Very similar · 37 shared holders

BAILLIE GIFFORD & CO National Pension Service SEB Asset Management AB

ABBV

AbbVie Inc.

AI score

Very similar · 41 shared holders

Capital Research Global Investors Capital World Investors Capital International Investors

JNJ

JOHNSON & JOHNSON

AI score

Very similar · 36 shared holders

Capital World Investors Capital Research Global Investors Clearbridge Investments, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VRTX on your watchlist

Track score changes the day VERTEX PHARMACEUTICALS INC / MA files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VRTX a good stock to buy?

13F Pro's AI-powered analysis of VERTEX PHARMACEUTICALS INC / MA (VRTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VRTX are available on the VRTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VRTX is classified as a large company.

Which hedge funds own VRTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VRTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of VERTEX PHARMACEUTICALS INC / MA's investment landscape.